Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer

被引:46
作者
Barton, TD
Collis, T
Stadtmauer, E
Schuster, MG
机构
[1] Univ Penn, Med Ctr, Div Infect Dis, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA
[3] Univ Washington, Seattle, WA 98195 USA
关键词
D O I
10.1086/318491
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Few studies have examined the specific incidence of infections after autologous bone marrow transplantation (BMT) or peripheral stem cell transplantation (PSCT) for treatment of breast cancer. We reviewed the medical records of 127 consecutive patients who underwent autologous BMT or PSCT for breast cancer at the University of Pennsylvania Medical Center from 1 May 1991 through 31 March 1995 and through 1 year of follow-up. The mean duration of neutropenia after transplantation was 10 days. Initial infections included catheter-site cellulitis (in 20 patients [16%]), bacteremia (17 [13%]), Clostridium difficile colitis (13 [10%]), and urinary tract infection (in 10 [8%]); there was only 1 documented invasive fungal infection (1% of patients). The mortality from infection was 2%. Infections during the 1 year follow-up included upper respiratory infections (11 patients [10%]) and dermatomal zoster (9 [8%]); neither was significantly associated with death. This group of patients who underwent BMT or PSCT for breast cancer had a low rate of infectious morbidity and mortality. Viral and fungal infections were rare despite inconsistent prophylaxis.
引用
收藏
页码:391 / 395
页数:5
相关论文
共 14 条
  • [1] SEQUENTIAL PROPHYLACTIC ORAL AND EMPIRIC ONCE-DAILY PARENTERAL ANTIBIOTICS FOR NEUTROPENIA AND FEVER AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT
    GILBERT, C
    MEISENBERG, B
    VREDENBURGH, J
    ROSS, M
    HUSSEIN, A
    PERFECT, J
    PETERS, WP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) : 1005 - 1011
  • [2] GLUCK S, 1994, BONE MARROW TRANSPL, V14, P989
  • [3] Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow stem-cell transplantation and comprehensive supportive care
    Holland, HK
    Dix, SP
    Geller, RB
    Devine, SM
    Heffner, LT
    Connaghan, DG
    Hillyer, CD
    Hughes, LL
    Miller, RL
    Moore, MR
    Winton, EF
    Wingard, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1156 - 1164
  • [4] HOYLE C, 1994, BONE MARROW TRANSPL, V14, P247
  • [5] KIRK JL, 1988, CANCER-AM CANCER SOC, V62, P2445, DOI 10.1002/1097-0142(19881201)62:11<2445::AID-CNCR2820621133>3.0.CO
  • [6] 2-I
  • [7] CIPROFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PROPHYLAXIS OF BACTERIAL-INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS - A RANDOMIZED, CONTROLLED TRIAL
    LEW, MA
    KEHOE, K
    RITZ, J
    ANTMAN, KH
    NADLER, L
    KALISH, LA
    FINBERG, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 239 - 250
  • [8] LJUNGMAN P, 1994, BONE MARROW TRANSPL, V13, P209
  • [9] ANTIMICROBIAL PROPHYLAXIS IN BONE-MARROW TRANSPLANTATION
    MOMIN, F
    CHANDRASEKAR, PH
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 123 (03) : 205 - 215
  • [10] Mossad SB, 1996, BONE MARROW TRANSPL, V18, P265